Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
O15554
UPID:
KCNN4_HUMAN
Alternative names:
IKCa1; KCa3.1; KCa4; Putative Gardos channel
Alternative UPACC:
O15554; Q53XR4
Background:
Intermediate conductance calcium-activated potassium channel protein 4, also known as IKCa1, KCa3.1, KCa4, or the Putative Gardos channel, plays a pivotal role in cellular processes. It forms a voltage-independent potassium channel activated by intracellular calcium, leading to membrane hyperpolarization and subsequent calcium influx. This protein is crucial for T-cell reactivation and proliferation, and it also contributes to the late stages of EGF-induced macropinocytosis.
Therapeutic significance:
The protein's involvement in Dehydrated hereditary stomatocytosis 2, a condition characterized by hemolytic anemia due to erythrocyte dehydration, underscores its therapeutic potential. Targeting KCa3.1 could offer novel treatment avenues for managing this genetic disorder and its complications, such as splenomegaly and cholelithiasis.